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Abstract 
The ErbB3 binding protein 1 (Ebp1) is an important regulator of transcription, affecting 
eukaryotic cell growth, proliferation, differentiation and survival. Ebp1 can also affect 
translation and co-operates with the polypyrimidine tract binding protein (PTB) to stimulate 
the activity of the internal ribosome entry site (IRES) of foot-and-mouth disease virus 
(FMDV). We report here the crystal structure of murine Ebp1 (p48 isoform), providing the 
first glimpse of the architecture of this versatile regulator. The structure reveals a core 
domain that is homologous to methionine aminopeptidases, coupled to a C-terminal 
extension that contains important motifs for binding proteins and RNA. It sheds new light on 
the conformational differences between the p42 and p48 isoforms of Ebp1, the disposition of 
the key protein-interacting motif (354LKALL358) and the RNA binding activity of Ebp1. We 
show that the primary RNA binding site is formed by a Lys-rich motif in the C-terminus and 
mediates the interaction with the FMDV IRES. We also demonstrate a specific functional 
requirement for Ebp1 in FMDV IRES-directed translation that is independent of a direct 
interaction with PTB.  
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Introduction 
Eukaryotic protein translation is predominantly initiated via a cap-dependent scanning 
mechanism (Pestova et al., 2001). However, during viral infection or cell death cap-
dependent translation initiation may be disabled and cap-independent mechanisms adopted 
instead. Cap-independent initiation requires direct recruitment of ribosomal subunits to an 
RNA sequence known as an internal ribosome entry site (IRES). This element, which often 
contains significant secondary structure elements, is usually contained within the 5´-
untranlated region of the mRNA (Hellen and Sarnow, 2001). Although IRESes were 
originally identified in the positive-sense, single-stranded RNA genomes of picornaviruses 
(Jang et al., 1988; Pelletier and Sonenberg, 1988), they have since been found in other RNA 
viruses (Hellen and Sarnow, 2001); it has been estimated that up to 10% of cellular mRNAs 
may contain IRES elements (Stoneley and Willis, 2004). 
In most cases only specific subsets of the canonical eukaryotic translation initiation factors 
(eIFs) are used for cap-independent mechanisms (Jackson, 2005), but a variety of other host-
cell proteins, termed IRES-specific cellular trans-acting factors (ITAFs), may also be 
required for efficient IRES function. For example, the rhinovirus IRES and several cellular 
IRESes require both the polypyrimidine tract binding protein (PTB) and upstream of N-ras 
(unr) for activity (Hunt et al., 1999; Mitchell et al., 2003), while the IRES from foot-and-
mouth disease virus (FMDV)—another picornavirus—requires both PTB and the 
proliferation associated factor ITAF45 (Pilipenko et al., 2000).  
In general ITAFs are RNA binding proteins recruited from their normal cellular functions and 
are believed to help in folding or stabilising the active form of the IRES to stimulate 
translation initiation (Hellen and Sarnow, 2001; Stoneley and Willis, 2004). ITAF45 was 
originally identified as a member of the PA2G4 family of proliferation regulated proteins 
(Radomski and Jost, 1995; Lamartine et al., 1997). However, the protein is now better known 
as Ebp1 (ErbB3 binding protein 1) as a result of more recent investigations that have revealed 
its interaction with the ErbB3 receptor (Yoo et al., 2000) and probed its role in mediating 
growth and proliferation signals. The Ebp1-ErbB3 interaction is regulated by the growth 
factor heregulin, which promotes the dissociation of Ebp1 and its relocation to the nucleus 
(Yoo et al., 2000) where it appears to function as a transcriptional repressor of genes 
regulated by E2F1 (Zhang et al., 2003; Zhang and Hamburger, 2004) and the androgen 
receptor (AR) (Zhang et al., 2002; Zhang et al., 2005a; Zhang et al., 2005b). This activity is 
linked to the ability of Ebp1 to inhibit proliferation and promote differentiation of breast and 
prostate cancer cell lines (Lessor et al., 2000; Zhang et al., 2005b). Lately, Ebp1 has also 
been shown to regulate cell growth and proliferation in plants (Horvath et al., 2006). 
The transcriptional repression mediated by Ebp1 depends on its participation in multi-protein 
complexes that interact with DNA promoter sequences of regulated genes (Xia et al., 2001; 
Zhang et al., 2003). With the exception of the co-repressor Sin3A (Zhang et al., 2005a) 
details of its interactions with other proteins have yet to be precisely determined. More 
recently Ebp1 has also been ascribed a role in regulating cell survival since its interaction 
with Akt kinase suppresses apoptosis (Ahn et al., 2006; Liu et al., 2006). This interaction 
depends on the phosphorylation of Ebp1 on Ser 360, which is also required for its interaction 
with ErbB3 (Lessor and Hamburger, 2001; Liu et al., 2006).  
In addition to its ability to interact with various proteins, Ebp1 binds DNA (Yamada et al., 
1994; Zhang and Hamburger, 2004) and an array of RNA targets including the FMDV IRES 
(Pilipenko et al., 2000), the 3´-untranslated region of bcl-2 mRNA (Bose et al., 2006) and 
ribosomal RNA (Squatrito et al., 2004), suggesting that Ebp1 can also regulate protein 
synthesis at a number of different levels. A further dimension to this role has appeared 
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recently with a report that Ebp1 can promote translation initiation by interacting with PKR 
and inhibiting the phosphorylation of the eIF2α subunit of eIF2 (Squatrito et al., 2006). 
Despite burgeoning interest in the role of Ebp1 in several important cellular functions, little is 
known about either the molecular structure of the protein or the interactions involved in 
ligand binding. To address these questions we have determined the crystal structure of Ebp1. 
We show that, as predicted (Pilipenko et al., 2000), the protein is structurally homologous to 
the type II methionine aminopeptidases (MAPs) but has a novel C-terminal extension 
containing binding motifs for proteins and RNA. Moreover, we provide direct evidence, 
using siRNA knockdown, of the specific involvement of Ebp1 in FMDV IRES mediated 
translation initiation and we have determined that the ability of Ebp1 to bind to the FMDV 
IRES maps to a lysine-rich sequence in the C-terminus of the protein. Together these findings 
give new insights into the structure and function of Ebp1 and provide a valuable framework 
for further dissection of its molecular mechanism. 
 
Results 
 
Crystal structure of Ebp1 
As an aid to crystallisation, sequence alignments with homologous type II MAPs (Pilipenko 
et al., 2000) of known structure were used to identify potentially unstructured termini of 
Ebp1 (Supp. Fig. S1). Following a series of deletion mutagenesis experiments, the construct 
Ebp1(8-360), which lacks the first seven and the last 34 amino acids of the protein, was 
found to be the most complete fragment that could be over-expressed solubly in E. coli and 
crystallised (Supp. Table S1). The 2.5 Å crystal structure of Ebp1(8-360) was phased by 
molecular replacement and refined to yield an Rfreeof 21.6% (Materials and methods; Table 
I). The refined model contains all the Ebp1 residues present in the construct.  
As expected, the protein fold is very similar to the two-domain structure of type II MAPs. 
The main or ‘catalytic’ domain (non-functional in Ebp1 - see below) is conserved in type I 
and II MAPs in prokaryotes, archaea and eukaryotes. In Ebp1 it is composed of residues 8-
243 and 307-337 and adopts a ‘pita-bread’ fold (Bazan et al., 1994) formed from two anti-
parallel β-sheets each flanked by a pair of α-helices (Figure 1A).This domain has a curved, 
globular structure and in MAPs the active site is contained within a deep pocket on its 
concave surface. The smaller insertion domain, one of the distinguishing features of type II 
MAPs (Liu et al., 1998; Tahirov et al., 1998), normally has a βαβααβ topology and forms a 
small anti-parallel β-sheet backed by a three-helix bundle. However, in Ebp1 this domain 
(residues 244-306) is slightly simplified by deletion of the middle helix  (Fig. 1A).  
Superposition of Ebp1 with the structures of type II MAPs using SSM (Krissinel and 
Henrick, 2004) revealed rms differences in Cα positions of 1.7 Å for both human MAP2 
(hMAP2; PDB ID 1kq9) and P. fu. MAP (PDB ID 1xgs) emphasising the overall similarity 
of these proteins. Nevertheless there are several notable differences between Ebp1 and type II 
MAPs. In particular, Ebp1 contains two extended loop insertions (loop 1: residue 63-71; loop 
2: residues 128-134), one helical insertion (residues 205-213) and a C-terminal extension 
(residues 338-394) that are not present in type II MAPs (Fig. 1B). These features are 
generally conserved in metazoan orthologues of Ebp1 (Supp. Fig. S2) and all occur on the 
surface of the protein. The novel C-terminal extension of Ebp1 wraps around the concave 
surface of the main domain and is stabilized by interactions with loop 2 and hydrophobic 
contacts between the 354LxxLL358 motif in the C-terminal helix and the body of the protein 
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(see Discussion). In contrast, hMAP2 contains a long N-terminal extension (residues 1-150) 
and a β-hairpin structure that are absent from Ebp1 and P. fu. MAP (Fig. 1B).  
Despite the overall similarity with type II MAPs, the structure of Ebp1 suggests that it does 
not retain methionine aminopeptidase activity since key residues in the active site are not 
conserved. This prediction was verified experimentally in methionine aminopeptidase assays 
that confirmed the activity of hMAP2 but found no detectable activity for Ebp1 (Supp Fig. 
S3). In functional MAPs the active site contains a pair of divalent cations co-ordinated by a 
strictly conserved set of residues (Asp 251, Asp 262, His 331, Glu 364, Glu 459 - hMAP2 
numbering) and a pair of flanking His residues (His 231 and His 339), that aid catalytic 
activity (Lowther and Matthews, 2002) (Fig. 1C). The crystal structure of Ebp1 reveals that 
this active site architecture is only partially conserved; in particular, Asp 262, Glu 459 and 
His 339 from human MAP2 are substituted by Asn 120, Lys 320 and Asp 196 respectively in 
Ebp1 (Fig. 1D, E). The electron density map shows that these changes are sufficient to 
abrogate metal binding, thus accounting for the absence of aminopeptidase activity. This is 
most likely due to the fact that the sidechain amino group of Lys 320 in Ebp1 occupies a 
position equivalent to one of the two cation sites in hMAP2, though other differences at the 
active site may also contribute to disruption of metal binding (Fig. 1D, E).  
 
A Lys-rich motif in the C-terminus of Ebp1 binds RNA 
Sequence alignments with homologous MAPs (Supp. Fig. S1) revealed two lysine rich 
regions, one (residues 65-72) within loop 1 and one (residues 364-373) within the C-terminal 
extension, both of which are well conserved in Ebp1 orthologues (Supp. Fig. S2). To probe 
the role of these Lys-rich motifs in RNA binding, electrophoretic mobility shift assays 
(EMSAs) were performed using radiolabelled full-length FMDV IRES RNA (Materials and 
Methods). Full-length Ebp1 bound the FMDV IRES with an apparent KD ~ 1-2 µM (Fig. 2A). 
Mutation of the N-terminal lysine rich motif 65KKEKEMKK72 to 65SSSSSSSS72 in the 
context of the full-length protein [Ebp1(1-394LM)] had no effect on RNA binding activity 
(Fig. 2B). In marked contrast, the construct Ebp1(1-360), in which the C-terminal Lys-rich 
sequence has been removed, was unable to bind the FMDV IRES (Fig. 2D) although a lesser 
deletion [Ebp1(1-375)] which retains the Lys-rich motif had wild-type binding activity (Fig. 
2C). These results demonstrate the critical importance of the sequence 
361SASRKTQKKKKKKAS375, containing the C-terminal Lys-rich region (underlined), for 
binding to FMDV IRES RNA by Ebp1.  
Toe-printing studies of Ebp1 previously indicated that the protein bound to a site located at 
the basal region of domain I of the FMDV IRES (Pilipenko et al., 2000). To further probe the 
specificity of the Ebp1-IRES interactions, we compared the binding of the protein to RNA 
transcripts encoding domains H (nt 280-336), I (nt 337-551) and JKL (nt 552-716) of the 
FMDV IRES. EMSAs performed using full-length Ebp1 indicated that the protein binds with 
broadly similar affinities (apparent KD ~ 0.2-1.0 µM) to all three RNA constructs (Fig. 2E-
G), although some minor variations were observed. For example, binding of Ebp1 to domains 
I and JKL was about 2-fold stronger than to domain H and the interaction of Ebp1 with 
domains JKL resulted in the formation of two distinct complexes with different affinities 
(Fig. 2G). Overall however, these data suggest that under our experimental conditions the 
binding of RNA by Ebp1 is non-specific. Further experiments confirmed this idea by 
showing that Ebp1 bound to the FMDV and EMCV IRESes (which differ in nucleotide 
sequence by about 50% (Drew and Belsham, 1994)) with equal affinity (Supp. Fig. S4); this 
result is consistent with previous reports that Ebp1 could bind to both IRESes (Pilipenko et 
al., 2000). Moreover, the non-specific nature of the interaction is underscored by the finding 
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that the protein has broadly similar affinity for single and double-stranded RNA and for 
double-stranded DNA targets (Supp. Fig. S5).  
Nevertheless, for all nucleic acid targets tested, deletion of the C-terminal Lys-rich sequence 
severely impaired binding of Ebp1, confirming that this is the binding motif for both RNA 
and DNA (Fig. 2; Supp. Figs S4, S5). The dependence of Ebp1 on such a motif readily 
accounts for its apparent lack of sequence specificity in binding RNA or DNA, at least in 
assays using purified components. This nevertheless raises interesting questions regarding the 
functional specificity of the protein (see Discussion). 
 
The interaction between the ITAFs PTB and Ebp1 is RNA dependent 
Ebp1 appears to operate synergistically with PTB in stimulating formation of 48S initiation 
complexes on the FMDV IRES (Pilipenko et al., 2000). We initially tried to probe the 
molecular basis of this phenomenon using dual-protein EMSAs in which RNA was pre-
bound to either Ebp1 or PTB and then incubated with the other protein, but this invariably 
resulted in extensive aggregation of the sample (data not shown). We therefore attempted to 
detect a direct, RNA-independent Ebp1-PTB interaction using pull-down assays. Ebp1 
constructs were transcribed and translated in vitro (Fig. 3A) and then pulled-down with either 
GST-PTB or, as a negative control, GST-Sex Lethal (GST-Sxl). The construct Raver1(1-455) 
was included as a positive control with known RNase sensitivity in its interaction with PTB 
(Rideau et al., 2006). Both Ebp1(1-394) and Ebp1(1-375) were pulled down with GST-PTB. 
However, this interaction was clearly abrogated by treatment with RNase to remove mRNAs 
generated during in vitro transcription (Fig.3B, bottom panel). Moreover, the construct 
Ebp1(1-360), which lacks the C-terminal RNA binding motif, was not pulled-down 
significantly above background levels, even in the absence of RNase treatment (Fig.3B, 
bottom panel). These results indicate that the positive interactions observed with Ebp1(1-394) 
and Ebp1(1-375) do not result from direct interaction between PTB and Ebp1 but are the 
consequence of both proteins binding to the same RNA molecule, consistent with the fact that 
both proteins have RNA-binding activity. It remains possible nevertheless that RNA-binding 
by either protein may induce conformational changes that permit formation of direct protein-
protein contacts. 
 
Role of Ebp1 in translation initiation  
Previous work demonstrating a role for Ebp1 in stimulating 48S initiation complex formation 
on the FMDV IRES relied exclusively on the use of in vitro biochemical toe-printing analysis 
(Pilipenko et al., 2000). To confirm a role for Ebp1 in FMDV IRES mediated translation 
initiation, we examined the effect of Ebp1 specific siRNAs on IRES activity in vivo (Fig. 4). 
Transfection of human embryonic kidney cells with Ebp1-specific siRNAs resulted in a 
significant reduction of Ebp1 levels, whereas PTB or GAPDH levels were unaffected 
(Fig. 4B). RNAi mediated reduction of Ebp1 levels resulted in a 55% reduction in FMDV 
IRES activity whereas EMCV IRES and cap-dependent translation were unaffected (Fig 
4A, C), consistent with previous observations on 48S complex formation (Pilipenko et al., 
2000). This confirms that Ebp1 exhibits sequence-specific stimulation of the FMDV IRES in 
vivo. 
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Discussion 
The crystal structure of Ebp1 provides new molecular insights into the transcriptional and 
translational roles of the protein, allowing us to re-interpret some of the existing functional 
data and to probe its mechanism more precisely. As anticipated from sequence alignments 
(Pilipenko et al., 2000), Ebp1 is structurally similar to the homologous type II MAPs (Fig. 1), 
though there are some significant differences. The structure reveals that the identity and 
conformation of the active site residues in MAPs is not maintained in Ebp1, resulting in the 
loss of aminopeptidase activity (Supp. Fig. S3. More significantly, the structure of Ebp1 
shows that at least part of the novel C-terminal extension in Ebp1 (residues 338-360) lies in a 
relatively extended conformation across the concave dorsal surface of the protein and is 
apparently available for interactions with proteins and RNA (see below).  
 
Predicted structural differences between the p42 and p48 isoforms of Ebp1  
There are two major isoforms of Ebp1 (p42 and p48) which have distinct cellular functions 
(Liu et al., 2006). The longer p48 isoform (used in our study), which localises to the 
cytoplasm and nucleolus, suppresses apoptosis but promotes cellular differentiation. In 
contrast the shorter p42 isoform, which lacks the N-terminal 54 amino acids present in p48, is 
confined predominantly to the cytoplasm where it acts to promote differentiation and 
suppress proliferation (Liu et al., 2006).  The crystal structure shows that the shorter isoform 
is missing the whole of helix α1 and half of α2 (Fig. 5A), structural features that are 
conserved in all known MAPs. The truncation of p42 removes K20 and K22, which form part 
of the nucleolar localisation signal (Squatrito et al., 2004). Such signals generally involve 
extended basic sequences (Fujiwara et al., 2006) and the structure of p48 Ebp1 shows that 
these residues are situated at solvent exposed positions close to the highly basic loop1 
(63IFKKEKEMK71 ; Fig 5A); this suggests that although loop1 has no demonstrated role in 
RNA binding (Fig. 2), it may contribute to a bipartite nucleolar localisation signal. 
The truncation of p42 also exposes of a large hydrophobic surface to solvent and may cause 
destabilisation of the protein, perhaps accounting for its significantly lower levels of 
expression (Liu et al., 2006). Consistent with this, we were unable to express Ebp1(55-394) 
in E. coli (Supp. Table S1). In eukaryotic cells the shorter isoform may be stabilised by 
refolding of the N-terminal region, perhaps involving the nearby C-terminal extension (Fig. 
5A, B), or by recruitment of novel protein partners. It is tempting to speculate that the 
conformational changes associated with the absence of residues 1-54 account for the ability 
of p42 Ebp1, but not p48, to interact with ErbB3 (Liu et al., 2006).  
 
Structure of the conserved LxxLL protein-binding motif in Ebp1  
Ebp1 has an important role in transcriptional repression which is reported to involve 
interaction with components of repressive complexes such as Rb (Xia et al., 2001), AR 
(Zhang et al., 2002) and Sin3A (Zhang et al., 2005a). In each case the C-terminal 70-80 
residues of Ebp1, which incorporates the novel extension identified in the structure (residues 
338-394; Fig. 1), have been shown to be required for these interactions. However, it is not yet 
clear if these interactions all involve direct contact with Ebp1 or are mediated by other 
components of the complex. Evidence for a direct protein-protein contact has been reported 
only for the Sin3A-Ebp1 interaction (Zhang et al., 2005a). In particular it has been shown 
that this is primarily mediated by the conserved LxxLL motif in the C-terminus of Ebp1 
(354LKALL358) (Zhang et al., 2005a). This motif has also been shown to be important for the 
interaction of Ebp1 with AR, which is known to have a binding site for the LxxLL motif (Hur 
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et al., 2004); however, a direct Ebp1-AR interaction remains to be demonstrated 
experimentally. 
The crystal structure of Ebp1 reveals that the 354LKALL358 sequence adopts the helical 
structure common for LxxLL motifs, allowing all three Leu sidechains to interact with a 
shallow hydrophobic pocket on the back-side of Ebp1 (Fig. 5C). The binding pocket for the 
motif in Ebp1 is primarily formed by amino acid sidechains from helices α3 and α4 that are 
completely apolar or have substantial hydrophobic moieties (L148, A152, R155, L156, A169, 
K172 and V173). Interestingly helices α3 and α4 adopt a different architecture to that 
observed in the helical LxxLL binding sites of nuclear receptors (Fig. 5C,D) revealing that 
the LxxLL motif can interact with structurally diverse binding sites. The interaction appears 
to at least partially conserve the “charge-clamp” mechanism previously detected in the ligand 
binding domains of nuclear receptors that bind this motif (Nolte et al., 1998; Hur et al., 2004; 
Plevin et al., 2005). Normally, a basic and an acidic amino acid sidechain serve to neutralise 
the partial charges associated with the helix dipole (Plevin et al., 2005). In the case of Ebp1, 
Arg 155 is positioned to interact with the negatively charged C-terminal end of the LxxLL 
helix, while Asp 351 interacts with the positively charged N-terminal end. Note however that 
Asp 351 is immediately upstream in the primary sequence from the helix so, while this 
interaction can stablise the helix, it may not otherwise contribute significantly to its 
interaction with the body of the protein. This weakening of the charge-clamp may be 
advantageous since it is evident that the 354LKALL358 motif from Ebp1 must peel away from 
the protein surface to interact with a binding partner such as Sin3A (Zhang et al., 2005a). 
Intriguingly, dissociation of the 354LKALL358 helix from the dorsal surface of Ebp1 makes 
the binding pocket available for another LxxLL motif; however, a binding partner that might 
take advantage of this site has not yet been identified. 
The structure also shows that Ser 360, the phosphorylation site of PKC (Liu et al., 2006), is 
solvent exposed and lies very close to the C-terminal end of the LxxLL helix (Fig. 5D,E). 
This residue is therefore likely to contact binding partners that interact with the LxxLL motif, 
suggesting that such interactions may be regulated by phosphorylation. Phosphorylation of 
this residue enhances binding to ErbB3 and Akt (Lessor and Hamburger, 2001; Liu et al., 
2006), but further work is required to establish a definitive role for the LxxLL motif in 
interactions with these binding partners. 
 
Ebp1 does not bind to PTB 
Ebp1 operates synergistically with PTB in forming 48S initiation complexes on the FMDV 
IRES (Pilipenko et al., 2000). Although PTB is known to interact with a variety of protein 
partners, particularly in its role as a regulator of alternative splicing [e.g. Raver1 (Gromak et 
al., 2003), Nova (Polydorides et al., 2000)], we were unable to detect a direct PTB-Ebp1 
interaction. This is consistent with the fact that Ebp1 lacks the conserved [S/G][I/L]LGxxP 
PTB-binding motif that has recently been identified within Raver1 (Rideau et al., 2006). Our 
results do show that PTB and Ebp1 can interact by binding to the same RNA molecule so 
their synergistic effect on FMDV translation initiation is likely to derive from concerted 
effects on the IRES structure. 
 
RNA binding activity of Ebp1 
The ability of Ebp1 (and its orthologues) to bind nucleic acid is well documented (Yamada et 
al., 1994; Radomski and Jost, 1995; Pilipenko et al., 2000; Squatrito et al., 2004; Zhang and 
Hamburger, 2004; Bose et al., 2006; Squatrito et al., 2006). With regard to RNA binding, 
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previous sequence analyses suggested that Ebp1 contains two conserved RNA binding 
domains, a σ70-like domain (residues 46-64) (Squatrito et al., 2004) and a double-stranded 
RNA binding domain (residues 91-156) (Squatrito et al., 2006), both of which were 
apparently confirmed when deletion of these domains abrogated RNA binding. Strikingly 
however, the crystal structure reveals that neither of these domains is present in Ebp1 (Supp. 
Fig. S6), but shows that deletion of the residues predicted to form them would cause loss of 
function by severely disrupting the protein fold. This is in fact the second time that the 
predicted helix-turn-helix motif of so-called σ70-like domains has been contradicted by a 
crystal structure (Ng et al., 2005), thus calling into question the functionality of this 
hypothetical motif (Wehner and Baserga, 2002).  
In contrast to the above studies, we showed that a lysine rich sequence 
(364RKTQKKKKKK373), situated within the portion of the C-terminus that had to be removed 
for crystallisation (suggesting that it may be relatively unstructured in the absence of ligand), 
is likely to be the key determinant for RNA binding (Fig. 2A-D). It is interesting to note that 
mutations within this motif partially inhibit nucleolar localisation (Squatrito et al., 2004), 
suggesting that RNA binding activity contributes to this function.  
The attribution of the primary RNA binding activity to a Lys-rich sequence suggests that 
RNA binding by isolated Ebp1 may not be sequence specific since a series of basic amino 
acids sidechains may primarily interact with the phosphate backbone of RNA ligands. 
Consistent with this idea, we observed similar binding by Ebp1 to a variety of RNA and 
DNA targets, including FMDV and EMCV IRES RNA (Supp. Fig. S4), distinct sub-domains 
of the FMDV IRES (Fig. 2E-G) and ssRNA, dsRNA and dsDNA samples (Supp. Fig. S5). 
The absence of detectable specific interactions with RNA or PTB throws into sharp relief the 
observation that Ebp1 nevertheless has a specific stimulatory effect on FMDV IRES-directed 
translation initiation but not on translation initiation directed by the closely related EMCV 
IRES (Figure 4). At present it is unclear how this functional specificity arises. Specific 
activation of the FMDV IRES by Ebp1 may depend on the intact RNA structure and also the 
presence of other ITAFs, including PTB. Consistent with this line of thinking, it has been 
suggested previously that Ebp1 and PTB may stabilise a conformation of the FMDV IRES 
that favours eIF4A/eIF4G binding (Pilipenko et al., 2000), thereby enhancing translation 
initiation, though alternative modes of ITAF action may operate (Mitchell et al., 2003). 
Indeed, the functional specificity probably only emerges once the full complement of 
initiation factors has assembled on the IRES. 
The plurality of interactions with proteins and RNA made by Ebp1 means that further work is 
required to dissect its roles both as a transcriptional regulator — and potential target for 
prostate cancer therapy (Zhang et al., 2005b) — and as an enhancer of IRES-mediated 
translation initiation. The structure reported here has begun to illuminate these functions in 
greater detail and will facilitate the design of more incisive functional investigations.  
 
 
Materials and Methods  
Plasmid construction: The plasmids pQE9-PTB1 (Conte et al., 2000) and pSP64 FMDV 
polyA (Stassinopoulos and Belsham, 2001) have been described previously. Ebp1 expression 
plasmids encoding the larger p48 isoform of the protein (Liu et al., 2006) were generated 
following cDNA amplification by PCR from the plasmid pET(His6-ITAF45) (Pilipenko et al., 
2000) using the primers detailed in Table S2. cDNA was digested with either BspHI/HindIII 
for constructs beginning at residue 1, or NcoI/HindIII for constructs beginning at residue 8, 
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and inserted into NcoI/HindIII digested pETM-11 (EMBL) creating constructs with an N-
terminal TEV cleavable His-Tag (Table S1). Ebp1(1-394LM) was generated by overlap PCR 
in the context of Ebp1(1-394) using the primers described (Supp. Table S2).   
Protein expression and purification: PTB proteins were expressed in SG13009 E. coli and 
purified on TALON resin (BD Biosciences) essentially as described previously (Conte et al., 
2000). Ebp1 constructs were expressed in Rosetta™(DE3) E.coli (Novagen). Cell pellets 
were lysed by sonication in 50 mM HEPES (pH7.0), 500 mM NaCl, 5 mM β-
mercaptoethanol supplemented with 0.1% Triton X-100 and a protease inhibitor cocktail 
(Sigma) and the protein purified using TALON (BD Biosciences) affinity resin. Samples for 
crystallographic screening were further purified as follows. The His-tag was removed with 
His-tagged TEV protease (Nunn et al., 2005) (1:10 TEV:target ratio) during overnight 
dialysis against 25 mM Tris (pH 8.0), 100mM NaCl, 5 mM β-mercaptoethanol. The cleaved 
His-tag and the His-TEV were subsequently removed using TALON resin. Further impurities 
were removed by passage through a 6 ml ResourceQ (Amersham) column (which did not 
bind Ebp1) in 25 mM Tris (pH 8.0), 100mM NaCl, 10 mM β-mercaptoethanol followed by 
gel filtration using a HR 30/10 Superdex75 (Amersham) column in 25 mM HEPES (pH 7.7), 
100 mM NaCl, 10 mM β-mercaptoethanol. Purified Ebp1 was concentrated to 10 mg/mL in 
10 mM HEPES (pH 7.7), 10 mM β-mercaptoethanol. GST-PTB (Pérez et al., 1997)and GST-
Sxl were expressed in E. coli and purified using glutathione sepharose 4B resin (Amersham) 
following the manufacturer’s protocol.  
Crystallisation and data collection: Crystals of Ebp1 (residues 8-360) were grown in 4-5 
days at 4°C from vapour-diffusion sitting drops at a protein concentration of 10 mg/mL in 10 
mM HEPES (pH 7.7), 10 mM  β-mercaptoethanol. The reservoir solution contained 20% 
PEG 8000 in 0.1 M HEPES (pH 7.5) and the drop was supplemented with 0.56 mM 
CYMAL-6. Diffraction data to 2.5 Å resolution, collected at room temperature using a single 
capillary-mounted crystal on beamline X11 at EMBL/DESY Hamburg, were processed and 
scaled using the CCP4 program suite (Collaborative Computer Project No. 4, 1994). The 
crystals belong to space-group P212121 and have one molecule in the asymmetric unit. Data 
collection statistics are summarised in Table 1.  
Structure solution and refinement: The diffraction data were phased using the molecular 
replacement program PHASER v1.2 (Storoni et al., 2004) with  a search model generated by 
superposition of the structures of the homologous human and Pfu MAPs (PDB IDs 1kq9 and 
1xgs respectively). Regions with non-conserved sidechains were removed from the search 
models, which were weighted according to the degree of identity (human MAP - 18%; Pfu 
MAP - 22%). This yielded a single solution with a Z-score of 10. 3Fo-2Fc and Fo-Fc electron 
density maps calculated using this solution showed clear features not present in the phasing 
model and allowed initiation of model building using ARP/wARP (Morris et al., 2003) 
starting with a truncated Ebp1 homology model generated using SWISSMODEL (Schwede et 
al., 2003) from the superposition described above. Manual model building and correction of 
protein register errors introduced during sequence alignment were performed using O (Jones 
et al., 1991). Structure refinement was completed using CNS (Brunger et al., 1998). 
RNA transcription and binding assays: FMDV IRES RNA (nts 280-717; numbering 
according to Pilipenko et al. (2000)) was generated using T7 RNA polymerase following 
linearization of pSP64-FMDV-polyA with EcoRI (Stassinopoulos and Belsham, 2001). 
Transcription templates for the FMDV IRES domain truncations were generated by PCR 
amplification from pSP64-FMDV-polyA with the primer pairs described in Table S2. All 
forward primers contained a T7 promoter. Radiolabelled RNA was produced either by 
incorporation of [α-32P] UTP during transcription, or by addition of [γ-32P] ATP to the 5' end 
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of the RNA using T4 polynucleotide kinase (Promega). The resultant RNA transcripts 
corresponded to – Domain H (nts 280-336); Domain I (nts 337-551) and Domain JKL (nts 
552-716). 
Prior to use in EMSAs all RNA constructs were refolded by heat denaturation for 5 min at 70 
°C followed by slow cooling to room temperature. EMSAs were performed essentially as 
described previously (Simpson et al., 2004) using 3-10 nM RNA and final binding conditions 
of 10 mM HEPES (pH 7.0), 3 mM MgCl2, 5 mM DTT, 100 mM KCl, 50 µg/ml tRNA, 40 
µg/ml HSA and 5% glycerol. Samples were analysed in 1% 0.5xTBE agarose gels and 
visualised by phosphomaging with a Fuji FLA5000. 
GST-pulldown assays: 35S-labelled proteins were generated from plasmid DNA using 
coupled transcription-translation assays (Promega) as per the manufacturer’s instructions. 
Equal activities of the 35S-labelled proteins were rotated for 3 hrs at 4°C with 35 pmoles of 
either glutathione-Sepharose 4B (Amersham) bound GST-Sxl or GST-PTB fusion protein in 
pull-down buffer (20 mM HEPES (pH 7.9), 100 mM KCl, 0.5 mM DTT, 10% glycerol, 0.2% 
Tween-20). The total reaction volume was 500 µl. After incubation beads were transferred to 
ZebaTM micro spin columns (Pierce) washed three times with pull-down buffer, and protein 
eluted with 2X SDS-sample buffer before analysis by 12% SDS-PAGE. Bound proteins were 
visualised by phosphoimaging with a Fuji FLA5000. For reactions requiring RNAse 
treatment 10 units of RNAse One (Promega) were added to the 35S-labelled protein 
immediately post translation and a further 10 units to each individual reaction mix. 
RNAi experiments and translation assays: siRNAs targeting either EGFP  (target sequence 
GGCTACGTCCAGGAGCGCACC) or Ebp1 (target sequence 
GTGAGGTGGAAAGGCGTTT) were purchased from Eurogentec. siRNA mediated 
reduction of Ebp1 in human embryonic kidney cells (293) was carried out using 
Lipofectamine 2000 according to the manufacturers instructions. 48 hours post transfection 
with siRNAs, cap and IRES-dependant translation was monitored by transfection of 5’ 
capped and 3’ polyadenylated in vitro transcribed dicistronic reporter mRNA of the form cap-
CAT-IRES-Luc (Roberts et al., 1998). In vitro transcribed reporter RNAs were capped by the 
incorporation of cap analogue [m7G(5´)ppp(5´)G; Promega] during transcription and 
subsequently polyadenylated using E.coli poly-A polymerase (Ambion). CAT and luciferase 
levels were determined 24 hours post transfection with reporter RNA using a CAT-specific 
ELISA (Roche) and luciferase assay (Promega) respectively. 
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Figure Legends 
Figure 1: Molecular Structure of Ebp1 and comparison with a type II human methionine 
aminopeptidase (hMAP2). (A) Ribbon diagram of the crystal structure of Ebp1 8-360; α-
helices are coloured pink and β-strands blue. (B) Superposition of Ebp1 in orange and 
hMAP2 in cyan [PDB 1kq9; (Nonato et al., 2006)]; insertions in Ebp1 are coloured dark red 
and those in hMAP2 dark blue. (C-E) Comparison of the active site of hMAP2 with the 
corresponding region in Ebp1. Sidechains of selected residues are shown as sticks for (C) 
hMAP2, (D) a superposition of hMAP2 and Ebp1 and (E) Ebp1. The colour coding is the 
same as for panel B. 
Figure 2: The C-terminal Lys-rich motif of Ebp1 binds the FMDV IRES RNA. 
Electrophoretic mobility shift assays were performed using 32P-labelled FMDV IRES RNA 
(nt 280-716) and two-fold dilutions of various Ebp1 proteins over the range 0.125-8 µM. (A) 
Ebp1(1-394); (B) Ebp1(1-394LM); (C) Ebp1(1-375) and (D) Ebp1(1-360). Ebp1 binds 
multiple regions of the FMDV IRES. Electrophoretic mobility shift assays were performed 
using 32P-labelled RNA and two-fold dilutions of full-length Ebp1 (residues 1-394) over the 
range 0.125-32 µM. (E) FMDV IRES Domain H (nts 280 – 336); (F) Domain I (nts 337 – 
551) and (G) Domain JKL (nts 552-716). (H) Schematic secondary structure of the FMDV 
IRES. 
Figure 3: Ebp1 interacts with PTB in an RNA dependent manner (A) 35S Methionine 
labelled coupled transcription-translation products for Ebp1 and control constructs. (B) GST 
pull-down assays between 35S-labelled Ebp1 constructs and 35 picomoles of either GST-Sxl 
(top panel) or GST-PTB (bottom panel). Reactions were performed in the absence (-) and 
presence (+) of RNAse treatment. 
Figure 4: Ebp1 is required for efficient translation from the FMDV IRES. (A) Schematic 
representation of  reporter RNAs used to analyse the effect of Ebp1 specific siRNAs on IRES 
mediated translation. (B) Western blot analysis of cells transfected with either EGFP or Ebp1 
specific siRNAs. Blots were probed with antisera to Ebp1, PTB or GAPDH. (C) Levels of 
the reporter proteins CAT and luciferase produced in cells transfected with either EGFP or 
Ebp1 specific siRNAs. Levels are expressed as a percentage of that observed in the EGFP 
siRNA transfected control. Assays were carried out in triplicate and the error bars represent 
the observed standard deviation. 
Figure 5: Structural features at the N- and C-termini of Ebp1. (A) The structure shows that 
the predicted p42 isoform (left) which starts at Met 55 lacks one and a half helices at the N-
terminus of the p48 isoform (indicated in grey in the structure on the right). This helix makes 
extensive hydrophobic contacts with the body of Ebp1 (coloured by atom type: carbon - 
orange; nitrogen - blue oxygen - red; sulphur - yellow); its removal exposes a large 
hydrophobic cleft on one face of the protein. The structure of p48 Ebp1 also illustrates the 
proximity of K20 and K22 to the lys-rich loop 1; together these features may constitute a 
bipartite nucleolar localisation signal (Squatrito et al., 2004; Fujiwara et al., 2006). (B) 
Position of the 354LKALL358 protein-binding motif at the C-terminus of Ebp1. Colouring is 
the same as in Fig. 1B except that residues from the motifs are highlighted in green. The 
surface of Ebp1 up to residue 337 is shown. Close-up views (in similar orientations) of the 
LxxLL motif from (C) Ebp1 and (D) the androgen receptor ((Hur et al., 2004); PDB - 1t7f). 
Residues from Ebp1 are colour coded as described above. Carbon atoms of the LxxLL motif 
of the peptide ligand of AR are cyan.  
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Table I: Data collection and refinement statistics 
DIFFRACTION DATA   
Space-group P212121 
a (Å) 49.15 
b (Å) 72.78 
c (Å) 115.62 
Wavelength (Å) 0.8123 
Resolution range (Å) 38.41 - 2.50 
Independent reflections 14714 
Multiplicitya 3.0 (3.0) 
Completeness (%) 98.9 (98.9) 
Mean I/(std. dev.) 10.4 (3.3) 
Rmerge (%)b 8.0 (41.0) 
  
MODEL REFINEMENT  
Nonhydrogen atoms/waters 2729/55 
Rmodel c / Rfree d (%) 18.3/21.6 
r.m.s deviation from ideal bond lengths (Å) 0.006 
r.m.s deviation from ideal angles (°) 1.27 
Ramachandran plot, favoured/additional (%) 91.8/7.6 
Average B-factor (Å2) 35.2 
PBD ID 2v6c 
 
aValues for the outermost resolution shell (2.64-2.50 Å) are given in parentheses. 
b Rmerge = 100xΣhΣi|Ihj - Ih|/ΣhΣiIhj where Ih is the weighted mean intensity of the symmetry 
related reflections Ihj 
c Rmodel = 100xΣh|Fobs - Fcalc|/ΣhFobs where Fobs and Fcalc are the observed and calculated 
structure factors respectively. 
dRfree is the Rmodel calculated using a randomly selected 5% sample of reflection data omitted 
from the refinement. 
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Supplementary Table S1: Expression of Ebp1 constructs in E. coli 
 
Construct Expression Solubility Comments 
Ebp1(1-394) ✔ ✔ No crystals obtained 
Ebp1(8-394) ✔ ✔ No crystals obtained 
Ebp1(8-360) ✔ ✔ Crystallised 
Ebp1(8-346) ✔ ✖ - 
Ebp1(8-336) ✔ ✖ - 
Ebp1(18-394) ✔ ✔ No evidence of TEV cleavage 
Ebp1(23-394) ✔ ✖ - 
Ebp1(23-360) ✔ ✖ - 
Ebp1(23-346) ✔ ✖ - 
Ebp1(23-336) ✔ ✖ - 
Ebp1(55-394) ✖ ✖ - 
Ebp1(55-360) ✖ ✖ - 
 
Constructs were cloned into pETM-11 for expression with an N-terminal TEVpro-cleavable His-tag. 
 
 
Wild-type Ebp1 sequence (murine): 
 
1   MSGEDEQQEQ TIAEDLVVTK YKMGGDIANR VLRSLVEASS SGVSVLSLCE  
51  KGDAMIMEET GKIFKKEKEM KKGIAFPTSI SVNNCVCHFS PLKSDQDYIL  
101 KEGDLVKIDL GVHVDGFIAN VAHTFVIGVA QGTQVTGRKA DVIKAAHLCA  
151 EAALRLVKPG NQNTQVTEAW NKVAHSFNCT PIEGMLSHQL KQHVIDGEKT  
201 IIQNPTDQQK KDHEKAEFEV HEVYAVDVLV SSGEGKAKDA GQRTTIYKRD  
251 PSKQYGLKMK TSRAFFSEVE RRFDAMPFAL RAFEDEKKAR MGVVECAKHE  
301 LLQPFNVLYE REGEFVAQFK FTVLLMPNGP MRITSGPFEP DLYKSEMEVQ  
351 DAELKALLQS SASRKTQKKK KKKASKTVEN ATSGETLEEN GAGD 
 
As reported previously (Pilipenko et al., 2000), the sequence contains two amino acid substitutions (T279A 
and K311R - underlined) in comparion to the original sequence reported for this protein (then known as 
Mpp1 - accession number NP_035249) (Nakagawa et al., 1997). 
 
Supplementary Table S2: DNA primers and templates used for the generation of Ebp1 expression 
constructs, truncated FMDV IRES constructs, ssRNA and dsRNA transcription and preparation of 
dsDNA samples. 
Construct Primers 
Ebp1(1-394) 5'–GTAGTAGCAGTAGGATCATGACGGGCGAAGACG–3' 
5'–GAGGGGACAAGCTTCAGTCCCCAGCTCC–3' 
Ebp1(1-375) 5'–GTAGTAGCAGTAGGATCATGACGGGCGAAGACG–3' 
5'–TCCACTGGTGGCATTCTCAAGCTTTTAGGAGGCCT–3' 
Ebp1(1-360) 5'–GTAGTAGCAGTAGGATCATGACGGGCGAAGACG–3' 
5'–GGTTTTTAAGCTTGCTTAACTCTGGAGAAGAGC–3' 
Ebp1(8-360) 5'–GGGCGAAGCCATGGAGCAGGAGCAAACTATCG–3' 
5'–GGTTTTTAAGCTTGCTTAACTCTGGAGAAGAGC–3' 
Ebp1(1-
394LM) 
5'–GTAGTAGCAGTAGGATCATGACGGGCGAAGACG-3' 
5'–ACCTGAACTCGACGAGCTTGACGAGCTGAAGATCTTCCCTGTC–3' 
5'–AGCTCGTCAAGCTCGTCGAGTTCAGGTATTGCCTTTCCTACC–3' 
5'–GAGGGGACAAGCTTCAGTCCCCAGCTCC–3' 
FMDV IRES 
Domain H 
(280 – 336) 
5'–TAATACGACTCACTATAGGGTGCAACTTGAAACTCCGCCTGG–3' 
5'-AGTACAAAATGTTACCCCTCTAGACC–3' 
FMDV IRES 
Domain I 
(337 – 551) 
5'–TAATACGACTCACTATAGGGTGTTTGACTCCACGCTCGA–3' 
5'–GTGTTTGAGTACCAGTATCAATGTCACC–3' 
FMDV IRES 
Domain JKL 
(552 – 716) 
5'–TAATACGACTCACTCACTATAGGGTGGTGACAGGCTAAGGATGC–3' 
5'–CATGTGTTCAGTGGTTATAAAAGGAAAGGTGCCTTCCTCCGG–3' 
ssRNA (T7 
primer and 
template) 
5´TAATACGACTCACTATAGGGAG 
3´ATTATGCTGAGTGATATCCCTCTAAAAAAAAAAAAAAAAAAAACGTTAAAAAAAAAAAAAAAAAAAA 
 
dsRNA (T7 
primer and 
template)  
5´TAATACGACTCACTATAGGGAG 
3´ATTATGCTGAGTGATATCCCTCTTTTTTTTTTTTTTTTTTTTTCGTTAAAAAAAAAAAAAAAAAAAA 
 
dsDNA 5´-CAAGGATATCGTGGTTTTAATGGACGGAGACACCATGCCTGGCC-3´ 
3´-GTTCCTATAGCACCAAAATTACCTGCCTCTGTGGTACGGACCGG-5 
 
 
NB: The cloning strategy used in the generation of the plasmid Ebp1(8-360) resulted in the substitution 
mutation Gln8Glu. Each forward primer for the FMDV IRES truncations incorporates a T7 promoter for 
direct transcription. 
Figure S1: Structure based sequence alignment of EBP1 with representative methionine 
aminopeptidases (MAPs). 
 
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
EBP1     ---------- ---------- ---------- ---------- ---------- ----------  
HUMAN    MAGVEEVAAS GSHLNGDLDP DDREEGAAST AEEAAKKKRR KKKKSKGPSA AGEQEPDKES  60 
E.COLI   ---------- ---------- ---------- ---------- ---------- ----------  
PFU      ---------- ---------- ---------- ---------- ---------- ----------  
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|           
EBP1     ---------- ---------- ---------- ---------- ---------- ----------  
HUMAN    GASVDEVARQ LERSALEDKE RDEDDEDGDG DGDGATGKKK KKKKKKRGPK VQTDPPSVPI 120 
E.COLI   ---------- ---------- ---------- ---------- ---------- ----------  
PFU      ---------- ---------- ---------- ---------- ---------- ----------  
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|            
EBP1     ---------- ---------- ---------- --MSGEDEQQ EQTIAEDLVV TKYKMGGDIA  28 
HUMAN    CDLYPNGVFP KGQECEYPPT QDGRTAAWRT TSEEKKALDQ ASE----EIW NDFREAAEAH 176 
E.COLI   ---------- ---------- ---------- ---MAISIKT PE------DI EKMRVAGRLA  21 
PFU      ---------- ---------- ---------- ---------- -M------DT EKLMKAGEIA  13 
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|            
EBP1     NRVLRSLVEA SSSGVSVLSL CEKGDAMIME E-TGKIFKKE KEMKKGIAF- -------PTS  79 
HUMAN    RQVRKYVMSW IKPGMTMIEI CEKLEDCSRK L-IKEN---- -GLNAGLAF- -------PTG 222 
E.COLI   AEVLEMIEPY VKPGVSTGEL DRICNDYIVN EQH------- ----AVSACL GYHGYPKSVC  70  
PFU      KKVREKAIKL ARPGMLLLEL AESIEKMIME L-G------- ----GKPAF- -------PVN  53 
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|            
EBP1     ISVNNCVCHF SPLKSDQDYI LKEGDLVKID LGVHVDGFIA NVAHTFVIGV AQGTQVTGRK 139 
HUMAN    CSLNNCAAHY TPNA-GDTTV LQYDDICKID FGTHISGRII DCAFTVT-FN -----PK--Y 273 
E.COLI   ISINEVVCHG IPD---DAKL LKDGDIVNID VTVIKDGFHG DTSKMFIVGK -----PTIMG 122 
PFU      LSINEIAAHY TPYK-GDTTV LKEGDYLKID VGVHIDGFIA DTAVTVRVGM -----E---E 104 
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|            
EBP1     ADVIKAAHLC AEAALRLVKP GNQNTQVTEA WNKVAHSF-- -------NCT PIEGMLSHQL 190 
HUMAN    DTLLKAVKDA TNTGIKCAGI DVRLCDVGEA IQEVMESYEV EIDGKTYQVK PIRNLNGHSI 333 
E.COLI   ERLCRITQES LYLALRMVKP GINLREIGAA IQKFVEAE-- -------GFS VVREYCGHGI 173 
PFU      DELMEAAKEA LNAAISVARA GVEIKELGKA IENEIRKR-- -------GFK PIVNLSGHKI 155 
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|            
EBP1     KQHVIDGEKT IIQNPTDQQK KDHEK-AEF- EVHEVYAVDV LVSSGEGKAK -DAGQRTTIY 247 
HUMAN    GQYRIHAGKT VPIIK----G G--EATR-ME E-GEVYAIET FGSTGKGVVH DD--MECSHY 383 
E.COLI   GQ-GFHEEPQ VLHYD----S RE-TN-VVL- KPGMTFTIEP MVNAGKKEIR TM--KDG--- 220 
PFU      ERYKLHAGIS IPNIY----R PH-DN-YVL- KEGDVFAIEP FATIGAGQVI EV--PPTLIY 206 
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|            
EBP1     KRDPSKQYGL KMKTSRAFFS EVERRFDA-- -MPFTLRAFE DEKKARMGVV ECAKHELLQP 304 
HUMAN    MKNFDVGHVP IRLPRTKHLL NVINENFGTL AFCRRWLDRL GESKYLMALK NLCDLGIVDP 443 
E.COLI   ---------- ---------- ---------- ---------- ---------- ----------  
PFU      MYVRDVPVRV AQARFLLAKI KREYGTLP-- FAYRWLQNDM PEGQLKLALK TLEKAGAIYG 264 
 
         ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|            
EBP1     FNVLYEK-EG EFVAQFKFTV LLMPNGPMRI TSGPFEPDLY KSEMEVQDAE LKALLQSSAS 363 
HUMAN    YPPLCDIKG- SYTAQFEHTI LLRPTCKEVV SRGDDY---- ---------- ---------- 478 
E.COLI   -WTVKTKDR- SLSAQYEHTI VVTDNGCEIL TLRKDDTIPA IISHDE---- ---------- 264 
PFU      YPVLKEIRN- GIVAQFEHTI IVEKDSVIVT TE-------- ---------- ---------- 295 
 
 
         ....|....| ....|....| ....|....| . 
EBP1     RKTQKKKKKK ASKTVENATS GETLEENGAG D   394 
HUMAN    ---------- ---------- ---------- - 
E.COLI   ---------- ---------- ---------- - 
PFU      ---------- ---------- ---------- - 
 
 
 
PDB files for Ebp1, human p67MAP2 (1kq9), P. fu MAP (1xgs) and E. coli MAP (2mat) were submitted for 
multiple 3D Secondary Structure Matching (SSM) at http://www.ebi.ac.uk/msd-srv/ssm/. Aligned PDB files 
were visualised in Pymol and the identified secondary structure mapped on to the sequence alignment file 
generated by SSM. Alpha helices are shown in red, beta sheets in blue. Regions in grey were not present in 
the input PDB files.  
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Figure S2: Sequence alignment of Ebp1 orthologues.  
 
 
                   ....|....|....|....|....|....|....|....|....|....|....|....| 
EBP1 MusMus        MSGEDEQ-----------QEQTIAEDLVVTKYKMGGDIANRVLRSLVEASSSGVSVLSLC 49 
HomSap             MSGEDEQ-----------QEQTIAEDLVVTKYKMGGDIANRVLRSLVEASSSGVSVLSLC  
DanRer             MSGDEEQ-----------QEQTIAEDLVVTKYKMGGDIANRVLRTLVDAATAGASLLNLC  
DroMe              MADVEKE-----------PEKTIAEDLVVTKYKLAGEIVNKTLKAVIGLCVVDASVREIC  
C_elegans          MVRKDSESSCSSDGSHTHEDYTLANDAVVTKYQVAAEITNAVLKEVLANIKEGAIAGDLC  
A_thal             MSSDDERD---------EKELSLTSPEVVTKYKSAAEIVNKALQVVLAECKPKAKIVDIC  
Spombe             MSTKEATS-------ETAVDYSLSNPETVNKYKIAGEVSQNVIKKVVELCQPGAKIYDIC  
Clustal Consensus  *   :              : :::.  .*.**: ..:: : .:: ::      .   .:*  
 
                   ....|....|....|....|....|....|....|....|....|....|....|....| 
EBP1 MusMus        EKGDAMIMEETGKIFKK-EKEMKKGIAFPTSISVNNCVCHFSPLKSDQ--DYILKEGDLV 106 
HomSap             EKGDAMIMEETGKIFKK-EKEMKKGIAFPTSISVNNCVCHFSPLKSDQ--DYILKEGDLV  
DanRer             EKGDAMIMEETGKIFKK-EKEMKKGIAFPTSISVNNCVCHFSPLKSDQ--DYLLKDGDLV  
DroMe              TQGDNQLTEETGKVYKK-EKDLKKGIAFPTCLSVNNCVCHFSPAKNDA--DYTLKAGDVV  
C_elegans          DLGDKLILEKTGKLYKK-EKNFTKGIAMPTCISIDNCICHYTPLKSEA--PVVLKNGQVV  
A_thal             EKGDSFIKEQTASMYKNSKKKIERGVAFPTCISVNNTVGHFSPLASD---ESVLEDGDMV  
Spombe             VRGDELLNEAIKKVYRT--KDAYKGIAFPTAVSPNDMAAHLSPLKSDPEANLALKSGDVV  
Clustal Consensus    **  : *   .:::.  *.  :*:*:**.:* ::   * :*  .:      *: *::*  
 
                   ....|....|....|....|....|....|....|....|....|....|....|....| 
EBP1 MusMus        KIDLGVHVDGFIANVAHTFVIGVAQGTQVTGRKADVIKAAHLCAEAALRLVKPGNQNTQV 166 
HomSap             KIDLGVHVDGFIANVAHTFVVDVAQGTQVTGRKADVIKAAHLCAEAALRLVKPGNQNTQV  
DanRer             KIDLGVHVDGFIANVAHSFVVGASKECPVTGRKADVIKAAHLCGEAALRLVKPGNQNSQV  
DroMe              KIDLGAHIDGFIAVAAHTIVVGAAADQKISGRQADVILAAYWAVQAALRLLKSGANNYSL  
C_elegans          KVDLGTHIDGLIATAAHTVVVGASKDNKVTGKLADLLRGTHDALEIAIRSLRPDTENTTI  
A_thal             KIDMGCHIDGFIALVGHTHVL---QEGPLSGRKADVIAAANTAADVALRLVRPGKKNTDV  
Spombe             KILLGAHIDGFASLVATTTVVS---EEPVTGPAADVIAAASAALKAAQRTIKPGNTNWQV  
Clustal Consensus  *: :* *:**: : .. : *:       ::*  **:: .:  . . * * ::..  *  :  
      
                   ....|....|....|....|....|....|....|....|....|....|....|....| 
EBP1 MusMus        TEAWNKVAHSFNCTPIEGMLSHQLKQHVIDGEKTIIQNPTDQQKKDHEKAEFEVHEVYAV 226 
HomSap             TEAWNKVAHSFNCTPIEGMLSHQLKQHVIDGEKTIIQNPTDQQKKDHEKAEFEVHEVYAV  
DanRer             TEAWNKISPSFKCTPIEGMLSHQLKQHVIDGEKTIIQNPTDQQKKDHEKAEFEVHEVYAV  
DroMe              TDAVQQISESYKCKPIEGMLSHELKQFKIDGEKTIIQNPSEAQRKEHEKCTFETYEVYAI  
C_elegans          TKNIDKTAAEFGLTPIENMLSHQLERNEIDGEKKIIQNSGEKQKGEIEKIKIDKHEAYAI  
A_thal             TEAIQKVAAAYDCKIVEGVLSHQLKQHVIDGNKVVLSVSS--PETTVDEVEFEENEVYAI  
Spombe             TDIVDKIATSYGCKPVAGMLSHQQEREVIDGKKQVILNPSDSQRSEMDTFTFEEGEVYGV  
Clustal Consensus  *.  :: :  :  . : .:***: ::  ***:* ::  .    .   :   ::  *.*.:  
      
                   ....|....|....|....|....|....|....|....|....|....|....|....| 
EBP1 MusMus        DVLVSSG-EGKAKDAGQR-TTIYKRDPSKQYGLKMKTSRAFFSEVERRFDAMPFTLRAFE 284 
HomSap             DVLVSSG-EGKAKDAGQR-TTIYKRDPSKQYGLKMKTSRAFFSEVERRFDAMPFTLRAFE  
DanRer             DVLISTG-EGKAKDAGQR-TTIYKRDPTKQYGLKMKTSRAFFSEVERRFAAMPFTLRAFE  
DroMe              DVIVSTG-EGVGREKDTK-VSIYKKS-EENYMLKMKASRALLAEVKTKYGNMPFNIRSFE  
C_elegans          DILFSTG-KGQPKDMDTR-TTVFRKNEQVSYQLKMKASRVFFSDVNKVHGPMPFSLRSFE  
A_thal             DIVASTG-DGKPKLLDEKQTTIYKKDESVNYQLKMKASRFIISEIKQNFPRMPFTARSLE  
Spombe             DILVSTSPSGKVKRSDIA-TRIYKKT-DTTYMLKLQASRKVYSEIQTKFGPFPFSTRNIS  
Clustal Consensus  *:: *:. .*  :  .   . ::::     * **:::** . ::::  .  :**. * :.  
      
....|....|....|....|....|....|....|....|....|....|....|....| 
EBP1 MusMus        DEKKARMGVVECAKHELLQPFNVLYEKEGEFVAQFKFTVLLMPNGPMRITSGPFEPDLYK 344 
HomSap             DEKKARMGVVECAKHELLQPFNVLYEKEGEFVAQFKFTVLLMPNGPMRITSGPFEPDLYK  
DanRer             DEKKARMGVVECAKHELLQPFNVLYEKEGEFVAQFKFTVLLMPNGPMRITSGPFEPDMYK  
DroMe              EETKARMGVVECVGHKMIEPFQVLYEKPSEIVAQFKHTVLLMPNGVNLVTGIPFEAENYV  
C_elegans          EEVKAKMGVVECEKYGLLVPYPVLYEKEGELVAQFKATVLVMPNGLLKIAGLPFDSDVYQ  
A_thal             -EKRARLGLVECVNHGHLQPYPVLYEKPGDFVAQIKFTVLLMPNGSDRITSHTLQ---EL  
Spombe             FDSRTNMGLNECTSHKLLFPYEVLLDKDGGIVAEFYSTIALTKKGTIILSDSEPKEDFIK  
Clustal Consensus   : ::.:*: **  :  : *: ** :* . :**::  *: :  :*   ::.   .       
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                   ....|....|....|....|....|....|....|....|....|....|.... 
EBP1 MusMus        SEMEVQDAELKALLQSSASRKTQKKKKKKASKTVENATSGETLEENGAGD---- 394 
HomSap             SEMEVQDAELKALLQSSASRKTQKKKKKKASKTAENPTSGETLEENEAGD----  
DanRer             SELEVQDSELKALLQSSASRKTQKKKKKKASKNAENATA----EENEGTE----  
DroMe              SEYSVAQEELKTLLAQPLGPVKGKGKGKKATAGAATKVETAPAVETKA------  
C_elegans          SDLTVKDPELQAVLKSALKPKK-KKEAKKDEPAAKKA-----------------  
A_thal             PKKTIEDPEIKGWLALGIKKKKGGGKKKKAQKAGEKGEASTEAEPMDASSNAQE  
Spombe             SDKKVEDPEIVALLETPIKVTKNKKKSKKPSKANE-------------------  
Clustal Consensus  ..  : : *:   *       .   : **                           
 
 
Orthologues to the murine Ebp1 sequence (P50580) were identified by Fasta analysis and the sequences 
aligned using ClustalW. Gaps in the sequences are represented by dashes. The Clustal consensus sequence 
highlights identity and conservation. Numbering relates to the Ebp1 sequence. 
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 Figure S3: Comparative aminopeptidase activity of hMAP2 and Ebp1.  
 
 
 
Both proteins were analysed by HPLC for their ability to remove the N-terminal Met from an octameric 
peptide substrate (MASKANQS), yielding the heptameric product (ASKANQS). The plasmid encoding a 
truncated but active form of hMAP2 (lacking residues 1-89) was kindly provided by Anthony Addlagatta 
  9 
and Brian Matthews (University of Oregon, USA). The protein was expressed and purified essentially as 
described (Addlagatta et al., 2005). Methionine aminopeptidase assays were performed by incubating the 
protein at 4 µM with 300 µM peptide substrate at 25°C for 0, 6 and 24 hrs in a buffer composed of 10 mM 
HEPES (pH 7.5), 100 mM NaCl and 1mM CoCl2. Reaction volumes were 200 µL. At the end of the 
incubation 50 µL of the reaction mix was diluted with an equal volume of water and applied to an ACE 5 
C18 reverse phase HPLC column (250x4.6 mm) (Hichrom Limited, Berckshire, UK). (A) The UV trace for 
the heptameric and octameric peptides in the absence of added protein at concentrations of peptide equal to 
those present in samples of the reaction solution.  A trace showing the heptameric product in the presence of 
hMAP2 is also shown. (B) UV traces of samples taken at 0 hrs, 6 hrs and 24 hrs from an incubation of the 
octameric substrate with hMAP2 as described above. In the presence of 1 mM CoCl2 cleavage is rapid, with 
a sharp decline in the substrate peak and a concomitant increase in the product peak at the earliest time point. 
In the absence of added CoCl2 no such change is observed. (C) UV traces of samples taken at 0 hrs, 6 hrs and 
24 hrs from an incubation of the octameric substrate with full length Ebp1. Incubation with Ebp1 had no 
affect on the concentration of octameric substrate in the reaction even after 24 hr incubation. Similarly, no 
product peak is observed.  
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Figure S4: Comparative binding of Ebp1(1-394) and Ebp1(1-360) to FMDV and EMCV IRES 
RNA using electromobility shift assays (EMSAs).  
 
The full-length protein, Ebp1(1-394) binds to the IRES from (A) FMDV and (B) EMCV with essentially the 
same affinity. Free and bound forms of RNA are indicated by ‘f’ and ‘b’ respectively on the right hand side 
of the figure. In each case, significant shifts are evident at 2-4 µM. (C,D) In contrast, only a marginal shift of 
both IRESes is observed at 60 µM Ebp1(1-360), the highest concentration used. Clearly, deletion of the C-
terminal Lys-rich motif severely impairs RNA binding to both IRESes (see main text). 
Methods: The IRES RNA samples were prepared by unlabelled in vitro transcription using the Promega 
RiboMAX kit following the manufacturers instructions. Following DNAseI digestion, RNA transcripts were 
purified using RNAeasy columns (Qiagen), precipitated using ethanol/sodium acetate and dissolved in 
RNase-free water to a concentration of 1.5 mg/ml. The RNA was annealed before use in binding experiments 
by heating to 70 °C for 5 minutes and slow-cooling to room temperature over 1 hr. Binding experiments 
were performed in 10 µL reaction volumes by mixing 100 ng of RNA (approx. 67 nM) with increasing 
concentrations of protein (0, 0.25, 0.5, 1, 2, 4, 8, 16, 32 and 60 µM) in 10 mM HEPES (pH 7.0), 3 mM 
MgCl2, 5 mM DTT, 100 mM KCl, and 5% glycerol and incubating at 25 °C for 10 minutes. Samples were 
then mixed with 2 µL of 50% (v/v) glycerol and 0.1 % (w/v) Bromophenol Blue and separated on 1% (w/v) 
agarose gels run in Tris-Borate (TB) (pH 8.3). 
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Figure S5: Comparative binding of Ebp1(1-394) and Ebp1(1-360) to single-stranded RNA 
(ssRNA), double-stranded RNA (dsRNA) and dsDNA using EMSAs.  
 
The full-length protein, Ebp1(1-394), is able to interact with (A) singled-stranded RNA, (B) double-stranded 
RNA and (C) double stranded DNA with similar affinities. Free and bound forms of RNA are indicated by 
‘f’ and ‘b’ respectively on the right hand side of the figure. Appreciable shifts are evident at 2-4 µM, similar 
to the concentrations required to shift the FMDV and EMCV IRES RNAs under these conditions. In 
contrast, only weak binding activity is exhibited by Ebp1(1-360) with (D) ssRNA, (E) dsRNA and (F) 
dsDNA; of these different types of ligand, ssRNA appears to bind tightest. 
Methods: RNA samples were prepared by in vitro transcription using the synthetic DNA templates and T7 
primers detailed in Table S2. Transcription reactions were performed using MEGAshortscript T7 kit 
(Ambion). DNaseI-treated RNA transcripts were purified on G25 microspin columns (GE Lifesciences) with 
a concentration 1 mg/ml. Transcription of the template for dsRNA yields a molecule with the sequence 
GGGAG(A20)GCAA(U20) that can fold into a stem-loop structure containing 20 A-U basepairs in the stem, 
topped by a GCAA tetraloop. The template for ssRNA is a modified version of the dsRNA template and 
yields a similarly sized RNA transcript in which all the A’s are replaced by U’s and has the sequence 
GGGAG(U20)GCAA(U20). Binding experiments were performed in 10 µL reaction volumes by mixing 100 
ng of RNA (approx. 250-630 nM) with increasing concentrations of protein (0, 0.25, 0.5, 1, 2, 4, 8, 16, 32 
and 60 µM) in 10 mM HEPES (pH 7.0), 3 mM MgCl2, 5 mM DTT, 100 mM KCl, and 5% glycerol and 
incubating at 25 °C for 10 minutes. Samples were then mixed with 2 µL of 50% (v/v) glycerol and 0.1 % 
(w/v) Bromophenol Blue and separated on 2% (w/v) agarose gels run in Tris-Borate (TB) (pH 8.3).  
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Figure S6: Ebp1 does not contain the previously predicted σ70-like motif or double-stranded 
RNA binding domain (dsRBD).  
 
 
 
σ70-like domains are predicted to adopt a helix-turn-helix motif (Wehner and Baserga, 2002), similar to the 
structure observed in some DNA binding proteins, such as the lambda repressor whereas the dsRBD forms 
an autonomous αβββα-fold (Doyle and Jantsch, 2002).  
(A) Ribbon diagram of a single monomer of the Lambda repressor [(Beamer and Pabo, 1992); PDB 1lmb] 
bound to DNA. The helix-turn-helix motif that binds in the major groove is shown in blue.  
(B) A double-stranded RNA binding domain (green) bound to RNA [(Ryter and Schultz, 1998); PDB 1di2].  
(C) Structure of Ebp1. The portions of the structure that were predicted to contain RNA-binding domains 
composed of a σ70-like helix-turn-helix motif (Squatrito et al., 2004) or a dsRBD (Squatrito et al., 2006) are 
shown in blue and green respectively. It is clear from the structure that these sequences adopt quite different 
folds within Ebp1. In fact the primary RNA-binding domain maps to a Lys-rich sequence 
(361SASRKTQKKKKKKAS375) that lies immediately beyond the C-terminus of the construct that was 
crystallised. 
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